BioSpace News Archive

Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that results from its real-world pre-conditioning study in Europe evaluating Sebacia Microparticles for treatment of facial acne has been accepted for an oral presentation

- Oral presentations include three of the five pivotal studies from AbbVie’s SELECT Phase 3 program to support regulatory submission for investigational upadacitinib in patients with moderate to severe rheumatoid arthritis

Magellan Health, Inc. today announced that it will report its earnings for the third quarter ending on September 30, 2018 at approximately 6:30 a.m. Eastern on Wednesday, November 7, 2018. At 9:00 a.m. Eastern on the same day, Magellan’s management will host a conference call and webcast to discuss earnings and other information.

Teva Pharmaceutical Industries Ltd. today announced that new data on COPAXONE® (glatiramer acetate injection), a product for relapsing forms of multiple sclerosis (RMS), will be presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Berlin, October 10-12, 2018.

Families come together to share patient experience and treatment needs at an international conference in Rome, Italy

There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating form of MS characterized by gradual, irreversible worsening of disability, largely independent of relapses

With the legalization of recreational cannabis coming to Canada in just over one week, Tweed, Uber, and MADD Canada are launching a national awareness campaign focused on informing Canadians on the risks of driving high.

Data to be presented as a Late-Breaking Clinical Trial at the 2018 VIVA Conference

Scientist.com, the life science industry’s leading online marketplace for outsourced research, announced the successful conclusion of a four-part podcast series on human biological samples and biobanking.

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK